BioSpace News Archive

Business

Revolutionary Erectile Dysfunction Treatment, GAINSWave®, Now Offered by Men’s Clinic Orlando in Florida

Men’s Clinic Orlando is implementing a non-invasive and drug free solution for Erectile Dysfunction called GAINSWave, which boasts a 75% success rate.

February 16, 2019
·
2 min read
Biotech Beach

Revolutionary Erectile Dysfunction Treatment, GAINSWave®, Now Offered by SDbody in California

SDbody is implementing a non-invasive and drug free solution for Erectile Dysfunction called GAINSWave, which boasts a 75% success rate.

February 16, 2019
·
2 min read
Job Trends

Revolutionary Erectile Dysfunction Treatment, GAINSWave®, Now Offered by Formula Wellness Center in Texas

Formula Wellness Center is implementing a non-invasive and drug free solution for Erectile Dysfunction called GAINSWave, which boasts a 75% success rate.

February 16, 2019
·
2 min read
Drug Development

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine Also Showed Risk of Progression or Death Reduced by 31 Percent

February 16, 2019
·
34 min read
Bio NC

Revolutionary Erectile Dysfunction Treatment, GAINSWave®, Now Offered by Signature Wellness in North Carolina

Signature Wellness is implementing a non-invasive and drug free solution for Erectile Dysfunction called GAINSWave, which boasts a 75% success rate.

February 16, 2019
·
2 min read
Drug Development

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Merck KGaA, Darmstadt, Germany announced the publication of results from an interim analysis of the pivotal JAVELIN Renal 101 trial online in the New England Journal of Medicine.

February 16, 2019
·
37 min read
Drug Development

AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib versus sorafenib in refractory advanced or metastatic renal cell carcinoma.

February 16, 2019
·
10 min read
Policy

Statement from eHealth Technologies Regarding Federal Indictment of Former CEO Michael Margiotta

eHealth Technologies’ Chief General Counsel and Chief Privacy Officer, Michael A. Sciortino, Esq., has issued the following statement

February 16, 2019
·
2 min read